New kidney drug tested for safety with statins and blood thinners
NCT ID NCT07515339
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to see how a new experimental drug for chronic kidney disease, nurandociguat, affects the way the body processes two common medicines: rosuvastatin (a cholesterol drug) and dabigatran (a blood thinner). Healthy adults would have taken these drugs alone and then again after taking nurandociguat to compare drug levels and side effects. The study was withdrawn before any participants enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Services | Clinical Research Services Mannheim - Phase one unit
Mannheim, Baden-Wurttemberg, 68167, Germany